Monteiro I, Nicolella V, Fiorenza M, Novarella F, et al. The ocrelizumab wearing-off phenomenon is associated with reduced immunomodulatory response and increased neuroaxonal damage in multiple sclerosis. J Neurol 2024 May 23. doi: 10.1007/s00415-024-12434.
PMID: 38777960